Brigatinib
A next-generation ALK inhibitor used to treat non-small cell lung cancer in patients whose tumors have an ALK gene rearrangement, particularly those who have progressed on other ALK inhibitors. It is designed to overcome resistance mechanisms and penetrate the brain, where lung cancer frequently spreads. It is taken orally once daily.
分子量
584.1000 g/mol
LogP
4.60
TPSA
85.90 Ų
リピンスキーの五則
適合
治療領域
作用機序
Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.
2D構造
Cite this structure
Embed this structure
SMILES
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1
InChI
InChI=1S/C29H39ClN7O2P/c1-35-15-17-37(18-16-35)21-11-13-36(14-12-21)22-9-10-24(26(19-22)39-2)33-29-31-20-23(30)28(34-29)32-25-7-5-6-8-27(25)40(3,4)38/h5-10,19-21H,11-18H2,1-4H3,(H2,31,32,33,34)
Molecular Formula
C29H39ClN7O2P
HBD / HBA
2 / 9
回転可能結合数
8
重原子数
40
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
A next-generation ALK inhibitor used to treat non-small cell lung cancer in patients whose tumors have an ALK gene rearrangement, particularly those who have progressed on other ALK inhibitors. It is designed to overcome resistance mechanisms and penetrate the brain, where lung cancer frequently spreads. It is taken orally once daily.
Inhibits anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase whose rearrangement or mutation drives oncogenic signaling in certain cancers.
Yes, Brigatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3545311. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 68165256. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="brigatinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/brigatinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/brigatinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/brigatinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="brigatinib"></drugfyi-drug>